Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.51 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SI | P14410 | 2/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087461 | 0.92 | ALOX5 (0.56) | ALOX5P2RY14GSTP1MAPTNPSR1 | |
| SCHEMBL6087375 | 0.88 | NPSR1 (0.58) | ALOX5P2RY14GSTP1MAPTNPSR1 | |
| SCHEMBL6086405 | 0.86 | LMNA (0.54) | ALOX5P2RY14GSTP1MAPTNPSR1 | |
| SCHEMBL6086702 | 0.85 | MGAM (0.56) | ALOX5P2RY14GSTP1MAPTNPSR1 | |
| SCHEMBL1358547 | 0.85 | ESR1 (0.56) | ALOX5P2RY14GSTP1ANO1MAPT | |
| SCHEMBL6088211 | 0.85 | MCL1 (0.50) | ALOX5P2RY14GSTP1MAPTNPSR1 | |
| SCHEMBL6087007 | 0.82 | MCL1 (0.53) | ALOX5P2RY14GSTP1MAPTNPSR1 | |
| SCHEMBL1359920 | 0.79 | P2RY14 (0.45) | ALOX5P2RY14GSTP1ANO1MAOB | |
| SCHEMBL17443554 | 0.79 | GSTP1 (0.56) | ALOX5GSTP1MAPTNPSR1MAOB | |
| SCHEMBL1360086 | 0.77 | MAOB (0.46) | ALOX5P2RY14GSTP1ANO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217032-B2 | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | ELI LILLY AND COMPANY (US) | 2012-07-10 | — | — | US | disclosed |
| CN-102250042-A | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | LILLY CO ELI | 2011-11-23 | — | — | CN | disclosed |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2011-11-17 | — | — | US | disclosed |
| CN-1910167-B | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | LILLY CO ELI | 2011-08-10 | — | — | CN | disclosed |
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | US | disclosed |
| CN-1910167-A | Selective estrogen receptor modulators for the treatment of vasomotor symptoms | LILLY CO ELI (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1709021-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005073204-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | ELI LILLY AND COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023917-A1 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms | GPER1, ESR1, HSD17B11 | ALOX5 351/4885P2RY14 499/4885GSTP1 2154/4885 |
| US-20110281847-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS | GPER1, ESR1, HSD17B11 | ALOX5 351/4885P2RY14 499/4885GSTP1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.